Progression to Critical Illness and Death in Patients With Breakthrough Hospitalizations

Geehan Suleyman,1,2* Raef Fadel,3 Ayman Alsaadi,3 Luis Ng Sueng,3 Ali Ghandour,3 Ahmad Alkhatib,3 Tarandeep Singh,3 Austin Parsons,3 Joseph Miller,4,5 Mayer Ramesh,1,6 and George Alangaden1,2

1Division of Infectious Disease, Henry Ford Hospital, Detroit, Michigan, USA; 2Department of Emergency Medicine, Henry Ford Hospital, Detroit, Michigan, USA; 3Wayne State University School of Medicine, Detroit, Michigan, USA; 4Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan, USA; and 5Department of Emergency Medicine, Henry Ford Hospital, Detroit, Michigan, USA

Background. Characterization of disease progression and outcomes after coronavirus disease 2019 (COVID-19)–related hospitalization in vaccinated compared with unvaccinated individuals is limited.

Methods. This was a retrospective case–control study of symptomatic vaccinated (cases) and unvaccinated (controls) participants hospitalized for COVID-19 between December 30, 2020, and September 30, 2021, in Southeast Michigan. Hospitalized adult patients with lab-confirmed COVID-19 were identified through daily census report. Breakthrough infection was defined as detection of severe acute respiratory syndrome coronavirus 2 ≥14 days after completion of the primary vaccination series. The association between prior vaccination and critical COVID-19 illness (composite of intensive care unit [ICU] admission, invasive mechanical ventilation [IMV], 28-day mortality) was examined.

Results. Two hundred ten (39%) fully vaccinated and 325 (61%) unvaccinated patients were evaluated. Compared with controls, cases were older, had more comorbidities (4 [3–7] vs 2 [1–4]; P < .001), and were more likely to be immunocompromised. Cases had less severe symptoms compared with controls (2 [1–2] vs 2 [2–3]; P < .001) and were less likely to progress to critical COVID-19 illness (33.3% vs 45.5%; P < .001); 28-day mortality was significantly lower in cases (11.0% vs 24.9%; P < .001). Symptom severity (odds ratio [OR], 2.59; 95% CI, 1.61–4.16; P < .001) and modified Sequential Organ Failure Assessment score on presentation (OR, 1.74; 95% CI, 1.48–2.06; P < .001) were independently associated with development of critical COVID-19 illness. Prior vaccination (OR, 0.528; 95% CI, 0.307–0.910; P = .020) was protective.

Conclusions. COVID-19-vaccinated patients were less likely to develop critical COVID-19 illness and more likely to survive. Disease severity at presentation was a predictor of adverse outcomes regardless of vaccination status.

Keywords. breakthrough hospitalizations; COVID-19; critical illness; mortality; risk factors.

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in >289 million cases and 5.4 million deaths globally as of January 2, 2022 [1]. COVID-19 vaccines are the leading strategy to change the course of the ongoing global pandemic. Randomized clinical trials have demonstrated COVID-19 vaccines to be highly effective in preventing symptomatic infections [2, 3], and observational studies have shown that COVID-19 vaccines are highly effective at preventing severe symptomatic disease, hospitalization, and death [4–7]. Early in the course of the pandemic, vaccine effectiveness against COVID-19-related hospitalization was found to be 97% in a national registry in Israel [8]. Vaccine effectiveness for the prevention of hospitalization due to COVID-19 was >85% in several postmarketing studies [4, 9].

Despite high vaccine efficacy, vaccine breakthrough infections are now commonly reported. As vaccines are not 100% effective, the number of breakthrough infections and hospitalizations is expected to increase when community spread is high, particularly with emergence of new COVID-19 variants. Lower vaccine effectiveness in preventing COVID-19-related hospitalization has been observed among older and immunocompromised patients in previous studies [4, 7, 10–12]. In a large multistate analysis, the vaccine effectiveness of the mRNA vaccines against COVID-19-associated hospitalization was 77% in the immunocompromised adults compared with 90% in the immunocompetent adults [12].

A recent study showed that vaccinated individuals with breakthrough infections had a lower risk of disease progression [7]. However, this study was limited by the small number of hospitalized patients. The objective of our study was to assess the impact of prior vaccination on disease progression and outcomes among hospitalized patients with COVID-19.
METHODS

Study Design and Participants
This was a case–control study of consecutive adult patients hospitalized with COVID-19 vaccine breakthrough infections in the Henry Ford Health System (HFHS), a comprehensive, integrated health care organization that includes 5 hospitals and 9 emergency departments (EDs) in Southeast Michigan, from December 30, 2020 (2 weeks after the introduction of the first COVID-19 vaccine), to September 30, 2021. All clinical outcomes were monitored for 28 days.

Hospitalized adult patients with positive SARS-CoV-2 diagnostic assays were identified through the daily census report. Cases included fully vaccinated patients hospitalized for symptomatic lab-confirmed COVID-19 from December 30, 2020, to September 30, 2021. Full vaccination was defined as completion of 2 doses of mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech) or 1 dose of JNJ78436735 (Janssen) ≥14 days before the testing date. Similarly, control patients were defined as consecutive unvaccinated adults hospitalized for symptomatic lab-confirmed COVID-19 within 2 weeks of hospitalization of identified cases. The first SARS-CoV-2 test within this eligibility period was used. Subjects were excluded if they were partially vaccinated (<14 days since completing the primary series or not completing the series before the specimen collection date), were not hospitalized for COVID-19 infection, had incomplete data, expired in the ED, or were asymptomatic with positive repeat polymerase chain reaction tests within 90 days of a previous SARS-CoV-2 infection.

Definitions
Vaccine breakthrough infection was defined as detection of SARS-CoV-2≥14 days after receipt of the primary COVID-19 vaccine series. Possible reinfection was defined as an infection in a person with a specimen collected ≥90 days after a positive SARS-CoV-2 diagnostic test. COVID-19-related hospitalization was defined as hospitalization in a symptomatic individual with a positive SARS-CoV-2 assay. COVID-19-related mortality occurred in a person with a documented COVID-19 diagnosis who died as a result of or from complications of COVID-19 disease.

Data Collection
A retrospective review of electronic medical records (EMRs) was performed to obtain demographic, clinical, and laboratory data. Race/ethnicity data were collected in the EMR by self-report using standard classification. Comorbidities associated with higher risk of developing severe outcomes of COVID-19 [13] were extracted using International Classification of Diseases (ICD), 10th revision, codes. Based on the most recent recorded body mass index (BMI), obesity was defined as a BMI ≥ 30 kg/m², and morbid obesity as BMI ≥ 40 (CDC obesity) [14]. Immunocompromised state was defined as presence of any of the following: immunosuppressive or immunomodulatory medication use, >20 mg of prednisone or equivalent per day for >2 weeks, history of hematopoietic stem cell transplant (HCT) or solid organ transplantation (SOT) and receipt of immunosuppressive therapy, solid tumor or hematologic malignancy on active treatment, and advanced or untreated HIV [15]. Cardiovascular disease was defined as presence or history of cardiomyopathy, coronary artery disease (CAD), or congestive heart failure (CHF). Chronic kidney disease (CKD) was defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria (KDIGO 2012) [16].

Vaccination status, including specific vaccine type and vaccination dates, was verified in the EMR and state immunization registry. Receipt of monoclonal antibodies (MABs) was recorded.

Severity of illness was determined using established guidelines [17], and patients were grouped into the following categories: 0 for asymptomatic infection, 1 for mild or moderate illness, 2 for severe illness, 3 for critical illness. Modified Sequential Organ Failure Assessment (mSOFA) scores were calculated and used as a well-validated predictor of mortality [18]. Oxygen saturation (SpO2) to fraction of inspired oxygen (FiO2) ratio was used as part of the mSOFA score to calculate patient hypoxia on admission.

Complications included acute kidney injury (AKI), need for renal replacement therapy (RRT), venous thromboembolism (VTE), secondary bacterial infections or candidemia, acute respiratory distress syndrome (ARDS), and shock requiring vasopressors. ARDS was defined in accordance with the Berlin Definition [19]. Acute kidney injury was identified according to the Kidney Disease: Improving Global Outcomes definition [16]. Receipt of COVID-19 treatment (corticosteroids, remdesivir, tocilizumab, or baricitinib) and antibiotics was evaluated. Primary outcomes included critical COVID-19 illness (ICU admission, invasive mechanical ventilation [IMV], 28-day mortality), and secondary outcomes included extubated alive, ventilator-free days, length of stay (LOS), and 28-day readmission. Ventilator-free days were calculated as: 28 days minus the number of days on mechanical ventilation. LOS was calculated from index admission to discharge in days, either alive or expired at the time of discharge.

Laboratory Studies
Methods for laboratory confirmation of SARS-CoV-2 infection have been previously described [20]. Creatinine, total bilirubin, absolute lymphocyte count, C-reactive protein (CRP), troponin, creatine phosphokinase (CPK), ferritin, D-dimer, and interleukin 6 were collected when available on admission.

Statistical Analysis
Descriptive statistics were performed to characterize each group in the case–control analysis. Groups were left unmatched in an attempt to fully describe each group. Frequency and count
data were displayed for categorical variables, mean with SD for normally distributed continuous variables, and median with interquartile range (IQR) for skewed continuous variables. The chi-square or Fisher exact test was applied for computation of categorical variables, and the t test or Mann-Whitney U test was used for continuous variables. Multivariable logistic regression was performed to model the relationship between COVID-19-related death and the following covariates: age, race, immunocompromised state, vaccination status, symptom severity, mSOFA, and intubation. Additionally, a second multivariable logistic regression was performed to model the relationship between critical COVID-19 development and the following covariates: age, immunocompromised state, vaccination status, symptom severity, mSOFA, and SpO2/FiO2 on admission. A third multivariable logistic regression was performed with fully vaccinated patients, modeling the following covariates: age, immunocompromised state, symptom severity, mSOFA score on presentation, and SpO2/FiO2 on admission. Such covariates were selected based on statistical significance in univariate analysis (P < .05). SpO2/FiO2 was used in the model for critical COVID-19 development given its utility in determining hypoxia and guiding medical decision-making in the mSOFA score. The testing level for all analyses was .05 for statistical significance. Analyses were performed using SAS 9.4 (SAS Institute Inc, Cary, NC, USA).

Patient Consent
The study was approved by the Institutional Review Board of HFHS, Detroit, Michigan. Informed consent was waived given that the study exclusively used deidentified data.

RESULTS
A total of 535 patients, consisting of 210 (39%) vaccinated or case patients and 325 (61%) unvaccinated patients or controls, were included in the case–control analysis. Eighty-five vaccinated patients were hospitalized for alternative diagnoses, had incomplete data, or died in the ED and were excluded.

Compared with unvaccinated patients, vaccine breakthrough cases were older (72.7 ± 13.4 vs 57.2 ± 17.3 years; P < .001), less likely to be Black (13.3% vs 32.6%; P < .001), and had a higher number of comorbidities (4 [3–7] vs 2 [1–4]; P < .001). Case patients had a lower average BMI (31.5 ± 7.8 vs 33.4 ± 9.3; P = .013), with no significant difference in sex. Comorbidities, including tobacco use history (52.9% vs 33.5%; P < .001), CKD (42.4% vs 18.5%; P < .001), COPD (25.7% vs 14.5%; P = .001), OSA (14.8% vs 8.3%; P = .019), diabetes mellitus (38.6% vs 27.4%; P = .007), cardiovascular disease (32.4% vs 12.6%; P < .001), and hypertension (71.4% vs 36.2%; P < .001), were more prevalent in the vaccinated group. Vaccinated patients were also more likely to be immunocompromised (P = .002). The majority of vaccinated patients received the BNT162b2 vaccine.

On presentation to the hospital, vaccinated patients were less symptomatic (96.7% vs 100%; P = .013) and had less severe symptoms on presentation (2 [1–2] vs 2 [2–3]; P < .001). There was no statistical difference in mSOFA score between the 2 groups, and there was no difference in rate of admission to the general practice unit (GPU) or ICU. Additionally, there was no significant difference in SpO2/FiO2 on admission. Vaccinated patients were less likely to require corticosteroids (82.9% vs 92.3%; P = .011) or tocilizumab (8.1% vs 17.5%; P = .002) during their index hospitalization. Table 1 demonstrates the results of the baseline characteristics of included patients.

During hospitalization, vaccinated patients were less likely to progress to critical COVID-19 illness (P < .001), including lower rates of admission to the ICU (32.4% vs 42.8%; P = .016), mechanical ventilation (13.3% vs 21.8%; P = .013), and 28-day mortality (11.0% vs 24.9%; P < .001). Additionally, vaccinated patients had more ventilator-free days (27 ± 4.2 vs 20.8 ± 2.6 days; P = .041) and lower rates of ARDS (10% vs 19.7%; P = .003) and venous thromboembolism development (3.3% vs 8.6%; P = .16). Otherwise, there was no significant difference in rates of being extubated alive (32% vs 10%; P = .158) or complications, including secondary bacterial or fungal infection, acute kidney injury requiring RRT, shock, hospital LOS, or readmission within 28 days for COVID-19. Table 2 highlights the complications and primary and secondary outcomes.

On multivariable logistic regression, symptom severity (OR, 2.59; 95% CI, 1.61–4.16; P < .001) and mSOFA score on presentation (OR, 1.74; 95% CI, 1.48–2.06; P < .001) were independently associated with development of critical COVID-19 illness in both groups. Additionally, age (OR, 1.05; 95% CI, 1.02–1.08; P < .001), symptom severity (OR, 17.4; 95% CI, 5.58–54.1; P < .001), mSOFA score on presentation (OR, 1.24; 95% CI, 1.04–1.47; P = .012), and IMV (OR, 4.66; 95% CI, 1.54–14.1; P = .006) were found to be independently associated with COVID-19-related death. Prior vaccination was protective against disease progression (OR, 0.528; 95% CI, 0.307–0.910; P = .020) and mortality (OR, 0.184; 95% CI, 0.080–0.440; P < .001). In the vaccinated cohort, only mSOFA score on admission (OR, 1.64; 95% CI, 1.31–2.05; P < .001) was significantly associated with development of critical COVID-19 illness. Figure 1 and Supplementary Tables 1–3 demonstrate the 3 multivariable logistic regression analyses with associated odds ratios. Vaccination status was significantly associated with a lower 28-day mortality on Kaplan-Meier analysis (P < .001), as demonstrated in Figure 2.

DISCUSSION
In this large case–control study, hospitalized patients with prior COVID-19 vaccination were less likely to experience severe...
illness and to progress to ICU-level care, IMV, or death as compared with unvaccinated controls. Additionally, vaccination status was the strongest independent predictor of survival of COVID-19 disease. Administration of corticosteroids or tocilizumab and complications such as VTE and ARDS also occurred less commonly among the vaccinated cohort. These

| Table 1. Baseline Characteristics of Vaccinated (n = 210) vs Unvaccinated (n = 325) Patients Hospitalized for COVID-19 |
|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|----------------|
| Total | Vaccinated | Unvaccinated | P Value* |
|-------|------------|--------------|----------|
| Baseline characteristics | n = 535 | n = 210 | n = 325 |
| Age, y | Mean (SD) | 63 (18) | 73 (13) | 57 (17) | .001 |
| Male sex | No. (%) | 262 (49.0) | 106 (50.5) | 156 (48.0) | .577 |
| Black race | No. (%) | 134 (25.0) | 28 (13.3) | 106 (32.6) | .001 |
| Health care worker | No. (%) | 7 (1.3) | 6 (2.9) | 1 (0.3) | .126 |
| BMI, kg/m² | Mean (SD) | 32.6 (8.8) | 31.5 (7.8) | 33.4 (9.3) | .013 |
| Comorbid conditions | Median (IQR) | 3 (2–5) | 4 (3–7) | 2 (1–4) | .001 |
| Obesity | No. (%) | 296 (55.3) | 107 (51.0) | 189 (58.2) | .001 |
| Tobacco smoking history | No. (%) | 220 (41.1) | 111 (52.9) | 109 (33.5) | .001 |
| Chronic kidney disease | No. (%) | 149 (27.9) | 89 (27.4) | 60 (18.5) | .001 |
| COPD | No. (%) | 101 (18.9) | 54 (25.7) | 47 (14.5) | .001 |
| Asthma | No. (%) | 67 (12.5) | 20 (9.5) | 47 (14.5) | .002 |
| Obstructive sleep apnea | No. (%) | 58 (10.8) | 31 (14.6) | 27 (8.3) | .019 |
| Diabetes mellitus | No. (%) | 170 (31.8) | 81 (38.6) | 89 (27.4) | .007 |
| Cardiovascular disease | No. (%) | 109 (20.4) | 68 (32.4) | 41 (12.6) | <.001 |
| Hypertension | No. (%) | 300 (56.1) | 150 (71.4) | 150 (46.2) | <.001 |
| Inflammatory bowel disease | No. (%) | 12 (2.2) | 6 (2.9) | 6 (1.8) | .422 |
| Rheumatoid arthritis | No. (%) | 7 (1.3) | 5 (2.4) | 2 (0.6) | .080 |
| Sarcoïdosis | No. (%) | 77 (14.4) | 74 (35.2) | 3 (0.9) | <.001 |
| Immunocompromised state | No. (%) | 224 (41.9) | 105 (50.0) | 119 (36.6) | .002 |
| HIV | No. (%) | 6 (1.1) | 4 (1.9) | 2 (0.6) | .167 |
| Solid organ transplant | No. (%) | 26 (4.9) | 17 (8.1) | 9 (2.8) | .005 |
| Systemic steroid use | No. (%) | 171 (32.0) | 72 (34.3) | 99 (30.5) | .355 |
| On active chemotherapy | No. (%) | 30 (5.6) | 25 (11.9) | 5 (1.5) | <.001 |
| Systemic steroid use | No. (%) | 38 (7.1) | 31 (14.8) | 7 (2.2) | <.001 |
| Vaccine type | No. (%) | | | |
| JUN78436735 | | | 25 (11.9) |
| mRNA1273 | | | 62 (29.5) |
| BNT162b2 | | | 123 (58.6) |
| Prior COVID-19 | No. (%) | 5 (0.9) | 4 (1.9) | 1 (0.3) | .061 |
| Symptoms on admission | No. (%) | 532 (99.4) | 203 (96.7) | 325 (100.0) | .013 |
| Symptom severity | Median (IQR) | 2 (2–3) | 2 (1–2) | 2 (2–3) | <.001 |
| MAB treatment | No. (%) | 40 (7.5) | 20 (9.5) | 20 (6.2) | .148 |
| Admit floor | No. (%) | | | |
| GPU | | | 377 (70.5) |
| ICU | | | 158 (29.5) |
| mSOFA on presentation | Median (IQR) | 2 (1–4) | 2 (1–4) | 2 (1–5) | .168 |
| Required O2 on admission | No. (%) | 384 (71.8) | 147 (70.0) | 237 (72.9) | .464 |
| SpO2/FiO2 on admission | Mean (SD) | 285.3 (130.6) | 293.5 (129.6) | 279.9 (130.9) | .239 |
| Treatments received | No. (%) | | | |
| Remdesivir | | | 340 (63.6) |
| Systemic corticosteroids | | | 474 (88.6) |
| Tocilizumab | | | 74 (13.8) |
| Baricitinib | | | 20 (3.7) |
| Antibiotics | | | 135 (25.2) |

Mean is presented with SD; median is presented with interquartile range. Abbreviations: BMI, body mass index; BMT, bone marrow transplant; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; FiO2, fraction of inspired oxygen; GPU, general practice unit; ICU, intensive care unit; IQR, interquartile range; MAB, monoclonal antibody; mSOFA, modified sequential organ failure assessment; O2, oxygen; SLE, systemic lupus erythematosus; SpO2, oxygen saturation. *Significant P values are bolded.
findings are consistent with prior studies that suggest that SARS-CoV-2 vaccination attenuates disease severity and critical COVID-19 development among vaccine breakthrough infections [7].

Among our cohort, Blacks were less likely to be vaccinated. As of December 20, 2021, only 36.5% of Blacks were fully vaccinated, compared with 50.4% of Whites and 52.3% of American Indians/Alaska Natives in Michigan [21]. In Metropolitan Detroit, 57.9% of the population was fully vaccinated [21]; however, in the City of Detroit, where 77% of the population is Black [22], only 41.6% of residents were fully vaccinated [21]. Studies suggest that Blacks are less likely to be vaccinated against COVID-19 compared with Whites or other racial and ethnic minority groups due to multiple challenges, including but not limited to distrust of the health care system, lack of access to a personal vehicle or reliable transportation, and lack of access to quality health care [23].

Risk factors for hospitalization and disease progression among vaccine breakthrough infections in our study are similar to those previously reported. Our vaccinated cohort was older and had a higher number of comorbidities compared with the unvaccinated group. Older age and underlying medical conditions are risk factors for disease progression, including death, in both vaccinated and unvaccinated patients [7, 8, 10, 11, 14, 24–28]. A higher proportion of older adults have been fully vaccinated compared with younger ones, and older adults may be more likely to be represented in breakthrough cases [27]. Nevertheless, a disproportionately large share of breakthrough COVID-19 hospitalizations occurs in those who are 65 years and older [27]. Similar to previous studies, the vaccinated cohort was more likely to have diabetes, hypertension, CAD, and CKD [26]. Older adults are more likely to be affected by underlying comorbidities, which predisposes them to greater risk for severe disease, regardless of vaccination status. They also have a less robust immune response than younger individuals, with waning immunity over time. An analysis demonstrated that more than two-thirds of breakthrough COVID-19 hospitalizations occurred among people ≥65 years of age who had certain chronic conditions, including hypertension, diabetes, and cardiovascular disease, compared with unvaccinated hospitalized younger patients [29].

Half of breakthrough hospitalizations occurred in immunocompromised patients, particularly among those who received systemic steroids, immunosuppressive agents, or chemotherapy. Multiple studies have demonstrated lower antibody response and vaccine effectiveness against vaccine breakthrough infection and hospitalization in the immunocompromised patient population, which predispose them to higher risk for worse outcomes [7, 12]. The risk varies by type, severity, and activity of the underlying condition, immunosuppressive treatment regimen, age, and comorbidities, among others. Boyarsky and colleagues evaluated more than 400 SOT recipients who received an mRNA COVID-19 vaccine and found that only 17% had detectable antibodies after 1 dose [30]. In a subsequent study of >650 transplant recipients, almost half had no detectable

Table 2. Complications and Outcomes of Vaccinated (n = 210) vs Unvaccinated (n = 325) Patients Hospitalized for COVID-19

| Complications | Total | Vaccinated | Unvaccinated | P Value* |
|---------------|-------|------------|--------------|----------|
| **Primary outcomes** | | | | |
| Critical COVID-19 | 218 (41.0) | 70 (33.3) | 148 (45.5) | <.001 |
| ICU admission | 207 (38.7) | 68 (32.4) | 139 (42.8) | .016 |
| Mechanical ventilation | 99 (18.5) | 28 (13.3) | 71 (21.8) | .013 |
| 28-d mortality | 104 (19.4) | 23 (11.0) | 81 (24.9) | <.001 |
| **Secondary outcomes** | | | | |
| Extubated alive* | 16 (16) | 9 (32) | 7 (10.0) | 158 |
| Ventilator-free d | 27.4 (3.2) | 27.0 (4.2) | 28.0 (2.6) | 0.041 |
| Hospital LOS, d | 5 (3–10) | 6 (3–10) | 5.5 (4–10) | 0.093 |
| 30-d readmission for COVID-19 | 37 (6.9) | 14 (6.7) | 23 (7.1) | 0.55 |
| **Complications** | | | | |
| Acute kidney injury | 184 (34.4) | 73 (34.8) | 111 (34.2) | .885 |
| Required renal replacement therapy | 28 (5.2) | 10 (4.8) | 18 (5.5) | .621 |
| Acute respiratory distress syndrome | 85 (15.9) | 21 (10.0) | 64 (19.7) | .003 |
| Venous thromboembolism | 35 (6.5) | 7 (3.3) | 28 (8.6) | .016 |
| Ventilator-associated pneumonia | 43 (8.0) | 12 (5.7) | 31 (9.5) | .113 |
| Bacteremia | 23 (4.3) | 11 (5.2) | 12 (3.7) | .390 |
| Candidemia | 2 (0.4) | 0 (0.0) | 2 (0.6) | .256 |
| Required vasopressor support | 30 (5.8) | 11 (5.2) | 19 (5.8) | .781 |

Mean is presented with SD; median is presented with interquartile range.
Abbreviations: COVID-19, coronavirus disease 2019; ICU, intensive care unit; IQR, interquartile range; LOS, length of stay.
*Significant P values are bolded.
*Analyzed based on the number of patients requiring mechanical ventilation (n = 99) and not the entire population.
response after 1 or 2 doses of the mRNA vaccines; 39% did not respond to the first dose but did to the second dose [31]. A recent report found that mRNA vaccine effectiveness ranged widely among immunocompromised subgroups and was lowest in SOT or HCT recipients and highest in patients with rheumatologic or inflammatory disorders [12]. In a systematic review of cancer, HCT, and SOT patients with COVID-19 infection, adult cancer and SOT patients had more comorbidities, greater need for intensive care support, and higher rates of hospital mortality than the general population [32].

Emerging data suggest that vaccination is not only associated with reduced risk of symptomatic infection but also severe COVID-19 illness [7]. Upon presentation, unvaccinated patients had more severe symptoms, which was a strong predictor of disease progression and death. For the vaccinated patients, a higher mSOFA score on presentation, which is a marker of disease severity and a prognostic indicator, was the only independent risk factor associated with critical illness progression. During the hospitalization, vaccinated patients were less likely to progress to critical COVID-19 illness compared with controls even though the mSOFA score was similar between the groups. Our findings support the observations of a recently published study, which demonstrated that hospitalized breakthrough cases were less likely to receive ICU-level care and IMV and less likely to progress to death [7].
Although mortality was lower after vaccination than in unvaccinated patients, it remained high in our hospitalized individuals: Overall mortality was 11%. This was higher than the 6.3% that was recently reported among 142 hospitalized patients [7]. Our breakthrough cases were older, with a mean age of 73, and had a higher prevalence of underlying comorbidities compared with previous reports [7, 25]. Additionally, half were immunocompromised. Age (OR, 1.05; 95% CI, 1.02–1.08; P < .001) was independently associated with COVID-19-related death in our cohort, which may be attributed to lower immune response to vaccines and waning immunity. Although prior vaccination was protective against disease progression and death, higher mSOFA score, which correlated with severe COVID-19, was independently associated with COVID-19-related death.

The association of disease severity at presentation with progression to critical COVID-19 and death in vaccinated patients highlights the role of early testing to detect breakthrough infections. Early diagnosis could lead to prompt treatment with novel therapies, including MABs and antiviral agents, in patients at high risk for severe outcomes.

Limitations
This study has a few limitations. It was a retrospective study conducted at a single large health system in Southeast Michigan; however, a diverse patient population was included in the study. We did not measure immunity or report vaccine effectiveness in our cohort due to multiple prior studies having assessed this. It is possible that vaccination status was not captured for individuals who received their vaccines out of state, and these patients could have been inadvertently excluded or placed in the control group. Although there is concern for selection bias, controls who met inclusion criteria were randomly selected.

CONCLUSIONS
Our findings suggest that SARS-CoV-2 vaccination attenuates disease severity and critical COVID-19 development among vaccine breakthrough infections. Disease severity at presentation was a predictor of adverse outcomes in both vaccinated and unvaccinated patients. In addition to the vaccines, early testing of symptomatic individuals and prompt administration of effective therapy such as MABs and/or oral antivirals should be the next priority to prevent disease progression and reduce mortality in high-risk patients regardless of vaccination status.

Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Acknowledgments
Financial support. There are no funding sources to report.
Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Johns Hopkins University & Medicine and Coronavirus Resource Centre. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Available at: https://coronavirus.jhu.edu/map.html. Accessed 2 January 2022.

2. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383:2603–15.

3. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384:403–16.

4. Bajema KL, Dahl RM, Prill MM, et al. Effectiveness of COVID-19 mRNA vaccines against COVID-19–associated hospitalization—five veterans affairs medical centers, United States, February 1–August 6, 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1294–9.

5. Grannis SJ, Rowley EA, Ong TC, et al. Interim estimates of COVID-19 vaccine effectiveness against COVID-19–associated emergency department or urgent care clinic encounters and hospitalizations among adults during SARS-CoV-2 B.1.617.2 (Delta) variant predominance—nine states, June–August 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1291–3.

6. Thompson MG, Stenehjem E, Grannis S, et al. Effectiveness of COVID-19 vaccines in ambulatory and inpatient care settings. N Engl J Med 2021; 385:1355–71.

7. Tenforde MW, Self WH, Adams K, et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA 2021; 326:2043–54.

8. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 2021; 2021:1819–29.

9. Self WH, Tenforde MW, Rhoads JP, et al. Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions—United States, March–August 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1337–43.

10. Kim PS, Schildhouse RJ, Saint S, et al. Vaccine breakthrough infections in veterans hospitalized with coronavirus infectious disease-2019: a case series. Am J Infect Control 2021; 50:273–6.

11. Tenforde MW, Patel MM, Ginde AA, et al. Effectiveness of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for preventing coronavirus disease 2019 hospitalizations in the United States. Clin Infect Dis 2022; 74(9):1515–1524.

12. Embi PJ, Levy ME, Naleway AL, et al. Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19–associated hospitalizations among immunocompromised adults—nine states, January–September 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1533–9.

13. Centers for Disease Control and Prevention. Underlying medical conditions. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html. Accessed 15 October 2021.

14. Centers for Disease Control and Prevention. Defining adult overweight and obesity. Available at: https://www.cdc.gov/obesity/adult/defining.html. Accessed 15 September 2021.

15. Centers for Disease Control and Prevention. COVID-19 vaccines for moderately to severely immunocompromised people. Available at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html. Accessed 15 September 2021.

16. Khwaja A. Kidney Disease: Improving Global Outcomes (KIDGO)—clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012; 120:s179–84.

17. National Institutes of Health. Clinical spectrum of SARS-CoV-2 infection. 2021. Available at: https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/. Accessed 15 September 2021.

18. Gissmok CK, Brown SM, Kuttler KG, et al. A modified Sequential Organ Failure Assessment score for critical care triage. Disaster Med Public Health Prep 2010; 4: 277–84.

19. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA 2012; 307:2526–33.

20. Food and Drug Administration. CDC 2019-novel coronavirus (2019-nCoV) realtime RT-PCR diagnostic panel. Available at: https://www.fda.gov/media/134922/download. Accessed 25 September 2021.

21. Michigan.gov. Coronavirus - COVID-19 vaccine dashboard. Available at: https://www.michigan.gov/coronavirus/resources/covid-19-vaccine/covid-19-dashboard. Accessed 20 March 2022.

22. United States Census Bureau. QuickFacts: Detroit city, Michigan. Available at: https://www.census.gov/quickfacts/detroitcitymichigan. Accessed 20 March 2022.

23. Centers for Disease Control and Prevention. COVID-19 vaccine equity. Available at: https://www.cdc.gov/coronavirus/2019-ncov/community/health-equity/vaccine-equity.html. Accessed 20 November 2021.

24. Bosh-Nissimov T, Orenbuch-Harroch E, Chowers M, et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clin Microbiol Infect 2021; 27:1652–7.

25. Juthani PV, Gupta A, Borges KA, et al. Hospitalisation among vaccine break-through COVID-19 infections. Lancet Infect Dis 2021; 21:1485–6.

26. Bosch W, Cowart JB, Bhakta S, et al. COVID-19 vaccine-breakthrough infections requiring hospitalization in Mayo Clinic Florida through August 2021. Clin Infect Dis. In press.

27. Centers for Disease Control and Prevention. COVID-19 data tracker. Available at: https://covid.cdc.gov/covid-data-tracker/#/datatracker-home. Accessed November 2021.

28. Suleyman G, Fadel RA, Malette KM, et al. Clinical characteristics and morbidity associated with coronavirus disease 2019 in a series of patients in metropolitan Detroit. JAMA Netw Open 2020; 3:e2012270.

29. Kf.org. "Breakthrough" COVID-19 hospitalizations among fully vaccinated patients occur most often among older adults and involve people with chronic health conditions. Available at: https://www.kf.org/coronavirus-covid-19/press-release/breakthrough-covid-19-hospitalizations-among-fully-vaccinated-patients-occur-most-often-among-older-adults-and-involve-people-with-chronic-health-conditions/. Accessed January 2022.

30. Boyarsky BJ, Werbel WA, Avery RK, et al. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. JAMA 2021; 325:1784–6.

31. Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA 2021; 325:2204–6.

32. Belsky JA, Tullius BP, Lamb MG, Sayegh R, Stanek JR, Auletta JJ. COVID-19 in immunocompromised patients: a systematic review of cancer, hematopoietic cell and solid organ transplant patients. J Infect 2021; 82:329–38.